16.64

0.83% -0.14

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $16.64, with a volume of 484.07K. It is down -0.83% in the last 24 hours and down -1.13% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Previous Close:

$16.78

Open:

$16.8

24h Volume:

484.07K

Relative Volume:

0.64

Market Cap:

$779.08M

Revenue:

$681.75M

Net Income/Loss:

$70.47M

P/E Ratio:

184.89

EPS:

0.09

Net Cash Flow:

$173.19M

1W Performance:

-2.29%

1M Performance:

-1.13%

6M Performance:

-43.95%

1Y Performance:

-36.78%

1-Day Range:

$16.53

$17.00

1-Week Range:

$16.29

$18.09

52-Week Range:

$11.16

$35.95

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

813-553-6680

Address

5401 WEST KENNEDY BOULEVARD, TAMPA, NJ

Employee

712

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	16.64	779.08M	681.75M	70.47M	173.19M	0.09
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

Nov 27, 2024

Connor Clark & Lunn Investment Management Ltd. Takes $1.21 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 27, 2024

Nov 25, 2024

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses (NASDAQ:PCRX) - Seeking Alpha

Nov 25, 2024

Segall Bryant & Hamill LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 25, 2024

Victory Capital Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 25, 2024

PCRX (Pacira BioSciences) Market Cap : $810.3 Mil (As of Nov. 25, 2024) - GuruFocus.com

Nov 25, 2024

(PCRX) On The My Stocks Page - Stock Traders Daily

Nov 25, 2024

Nov 22, 2024

Pacer Advisors Inc. Purchases 2,799,434 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 22, 2024

Nov 20, 2024

Global Alpha Capital Management Ltd. Sells 49,560 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Empowered Funds LLC Takes $3.29 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth - MSN

Nov 18, 2024

Janney Montgomery Scott LLC Acquires New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 18, 2024

Nov 16, 2024

Impax Asset Management Group plc Boosts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Nov 16, 2024

Nov 14, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat

Nov 14, 2024

Nov 13, 2024

Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com Canada

Nov 13, 2024

Nov 12, 2024